Last reviewed · How we verify

Adrenaline nasal pack

Shaheed Mohtarma Benazir Bhutto Institue of Trauma · Phase 2 active Small molecule Under review

Adrenaline nasal pack is a Sympathomimetic Small molecule drug developed by Shaheed Mohtarma Benazir Bhutto Institue of Trauma. It is currently in Phase 2 development for Anaphylaxis treatment.

Adrenaline nasal pack works by releasing adrenaline into the nasal passages to rapidly increase blood pressure and improve breathing in cases of anaphylaxis or severe allergic reactions.

Adrenaline nasal packs are used in nasal surgeries, such as septoplasty, to prevent postoperative agitation. The mechanism of adrenaline nasal packs is through the action of adrenaline as a small molecule, although the specific details of its mechanism are not provided in the available information.

Likelihood of approval
15.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameAdrenaline nasal pack
SponsorShaheed Mohtarma Benazir Bhutto Institue of Trauma
Drug classSympathomimetic
TargetAdrenaline receptor
ModalitySmall molecule
Therapeutic areaEmergency Medicine
PhasePhase 2

Mechanism of action

Adrenaline, also known as epinephrine, is a potent stimulant that increases heart rate, blood pressure, and breathing rate. When administered via a nasal pack, it quickly reaches the bloodstream and helps to counteract the life-threatening symptoms of anaphylaxis, such as difficulty breathing and rapid heartbeat.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Adrenaline nasal pack

What is Adrenaline nasal pack?

Adrenaline nasal pack is a Sympathomimetic drug developed by Shaheed Mohtarma Benazir Bhutto Institue of Trauma, indicated for Anaphylaxis treatment.

How does Adrenaline nasal pack work?

Adrenaline nasal pack works by releasing adrenaline into the nasal passages to rapidly increase blood pressure and improve breathing in cases of anaphylaxis or severe allergic reactions.

What is Adrenaline nasal pack used for?

Adrenaline nasal pack is indicated for Anaphylaxis treatment.

Who makes Adrenaline nasal pack?

Adrenaline nasal pack is developed by Shaheed Mohtarma Benazir Bhutto Institue of Trauma (see full Shaheed Mohtarma Benazir Bhutto Institue of Trauma pipeline at /company/shaheed-mohtarma-benazir-bhutto-institue-of-trauma).

What drug class is Adrenaline nasal pack in?

Adrenaline nasal pack belongs to the Sympathomimetic class. See all Sympathomimetic drugs at /class/sympathomimetic.

What development phase is Adrenaline nasal pack in?

Adrenaline nasal pack is in Phase 2.

What are the side effects of Adrenaline nasal pack?

Common side effects of Adrenaline nasal pack include Nausea, Headache, Palpitations, Tremors, Dizziness.

What does Adrenaline nasal pack target?

Adrenaline nasal pack targets Adrenaline receptor and is a Sympathomimetic.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing